The purpose of the present study was to assess the effects of early initiation of statin treatment on midterm major adverse cardiac events (MACEs) after acute myocardial infarction (AMI). Between October 2005 and December 2006, 621 AMI patients (439 ST-segment and 182 non-ST-segment elevation MI) were registered and followed prospectively. Early initiation of statin treatment was defined as prescription of statins during hospitalization (n=545), and the control group was not prescribed statins (n=76). During the 6-month follow-up, 22 patients died: 7 patients from the control group (9%) and 15 patients from the statin group (3%) (p=0.004). Six-month MACEs (including cardiac death, MI, and target vessel revascularization) occurred less frequently in the statin group than in the control group (14% vs. 24%, p=0.034). Baseline high-sensitivity C-reactive protein (hs-CRP) was significantly higher in patients who experienced cardiac death than in patients without cardiac death (12.8±10.2 mg/dl vs. 2.1±3.0 mg/dl, p＜0.001). Multivariate analysis showed that early statin therapy and the baseline hs-CRP level were independent predictors of 6-month mortality [odds ratio (OR)=0.078, 95% CI: 0.008∼0.808, p=0.032, and OR=1.314, 95% CI: 1.149∼1.501, p＜0.001, respectively). High inflammatory status is associated with poor prognosis, and early initiation of statin treatment after AMI could decrease the mid-term mortality rate.
Introduction
Hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) therapy lowers mortality and morbidity in coronary artery disease and other atherosclerotic vascular disease, as evidenced by multiple large-scale clinical trials. [1] [2] [3] [4] Statins inhibit mevalonate synthesis and are effective at lowering low-density lipoprotein (LDL)-cholesterol. Beyond lowering lipids, statins have favorable effects on vascular inflammation, 5, 6 endothelial function, 7, 8 and platelet adhesion and thrombosis. 9 The beneficial effects of statins mostly rely on their antiinflammatory properties. 10 Previous studies of patients with acute myocardial infarction (AMI) have suggested that early initiation of statins is associated with a significantly lower occurrence of early complications, a reduced infarct size, and better in-hospital survival. 11, 12 However, to the best of our knowledge, few data are available regarding the effects of early initiation of statin treatment on midterm clinical outcome including cardiac mortality. In the present study, we assessed the effects of early initiation of statin treatment on midterm clinical events after AMI in a real-world setting.
Materials and Methods
Study population
From Risk factors were reviewed via retrospective chart review.
Laboratory analysis
All laboratory values were measured after the patients had fasted overnight. The serum levels of total cholesterol, 
End points
The primary end point was occurrence of cardiac death during the 6-month follow-up. The secondary end point was the occurrence of the composite of cardiac death, MI, and target vessel revascularization during the 6-month follow-up. All deaths were considered to be of cardiac origin unless a noncardiac origin was established clinically or at autopsy. MI was defined by the presence of recurrent ischemic symptoms or electrocardiographic changes accompanied by a creatine kinase level that was more than twice the upper limit of the normal range or ＞50% higher than the value during the index hospitalization (with an elevated MB isoform level). Target vessel revascularization included bypass surgery or repeat PCI of the target vessels.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS)
for Windows, version 15.0 (Chicago, Illinois) was used for all analyses. Continuous variables were presented as the the independent predictors of 6-month cardiac mortality.
A p value ＜0.05 was considered statistically significant.
Results

Patient demographics, medications, and lipid profiles
There were no significant differences in patient demographics or medications except for statin between the groups. The levels of LDL-cholesterol and hs-CRP were almost the same between the two groups ( Table 1) .
Coronary angiographic and procedural findings
There were no significant differences in baseline coronary angiographic findings and procedural results between the two groups ( Table 2) . A total of 76% in the statin group and 78% in the nonstatin group had complex lesions, and 51% in the statin group and 53% in the nonstatin group had multivessel disease. Stents were used in 93% of the patients. Bare-metal stents were used in 18% and drugeluting stents were used in 82% of the patients. The occurrence of post-PCI no-reflow phenomenon [which was defined as post-PCI thrombolysis in myocardial infarction (TIMI) flow grade 0, 1, and 2] was not significantly different between the groups.
Primary and secondary end points during the 6-month follow-up
Follow-up data were available for all patients. During the 6-month follow-up, 22 patients died (4%), including 7 patients from the control group (9%) and 15 patients from the statin group (3%) (p=0.004). Six-month major adverse cardiac events (including cardiac death, MI, and target vessel revascularization) occurred less frequently in patients who had taken early statin therapy than in patients who had not taken statin therapy (Fig. 1 ).
Factors relating to cardiac death during the 6-month follow-up
The patients who experienced cardiac death were older ACC/AHA, American College of Cardiology/American Heart Association; TIMI, Thrombolysis In Myocardial Infarction. Fig. 1 . Incidences of mortality, myocardial infarction (MI), target vessel revascularization (TVR), and total major adverse cardiac events (MACE) in the statin group and nonstatin group at the 6-month follow-up. and had a higher Killip class on admission than did the patients without cardiac death. The patients who experienced cardiac death had more atrial fibrillation and ventricular tachyarrhythmia and had more deteriorated left ventricular function on admission than did the patients without cardiac death. Serum creatinine was significantly higher, creatinine clearance was significantly lower, and the HDL-cholesterol level was significantly lower in the patients who experienced cardiac death than in the patients without cardiac death. Baseline hs-CRP was significantly higher in the patients who experienced cardiac death than in the patients without cardiac death (Table 3 ). There were no significant differences in types or daily dosages of statins used between the patients who experienced cardiac death and those who did not. There were no significant differences in the infarctrelated artery, ACC/AHA lesion type, or baseline or post- PCI TIMI flow grade between the groups. However, multivessel disease was more frequently observed in the patients who experienced cardiac death than in those who did not (Table 4) .
Independent predictors relating to cardiac death during the 6-month follow-up
Multiple logistic regression analysis was performed to determine independent predictors of 6-month cardiac mortality. There are several limitations to be mentioned. First, this single-center study included only a small number of patients.
Second, we did not assess the differences in clinical outcomes according to the kinds of statins and the dosages of statins used. Third, we included all AMI patients regardless of treatment methods (PCI or medical therapy).
However, treatment methods were not an independent predictor of mortality in the present study.
In conclusion, in this analysis of 621 AMI patients, high inflammatory status was associated with poor prognosis, and early initiation of statin treatment after AMI could decrease the midterm mortality rate.
